Actively Recruiting
Evaluating Rocbrutinib Versus Dimethyl Fumarate in Adults With PRL-Positive Relapsing-Remitting Multiple Sclerosis
Led by Guangzhou Lupeng Pharmaceutical Company LTD. · Updated on 2026-08-20
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating rocbrutinib LP-168, an oral BTK inhibitor, in adults aged 18 to 65 with paramagnetic rim lesion PRL-positive relapsing-remitting multiple sclerosis RRMS. This Phase IIa randomized, controlled, open-label study compares rocbrutinib with dimethyl fumarate DMF to assess their effects on PRL lesions using 7T MRI scans. The aim is to evaluate the efficacy and safety of rocbrutinib over the treatment period. Participants are randomly assigned in a 21 ratio to receive either rocbrutinib 25 mg once daily on an empty stomach or DMF starting at 120 mg twice daily, increasing to 240 mg twice daily after 7 days. The main treatment period lasts 24 weeks. Those in the rocbrutinib group who remain relapse-free and show potential benefit may continue the treatment in an open-label extension up to 48 weeks. During the study, participants undergo MRI scans at screening, baseline, and multiple timepoints to measure changes in the number and volume of PRL lesions. Other assessments include disability status, relapse rates, and physical tests such as walking and hand coordination. Safety is closely monitored through adverse event tracking and laboratory tests throughout the treatment and a 4-week safety follow-up after treatment ends.
CONDITIONS
Brief Title
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Research Team
D
Dr. De-Cai Tian, M.D., Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here